- Home
- PSHG vs TENX Comparison
PSHG vs TENX Comparison
Compare PSHG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- TENX
- Stock Information
- Founded
- PSHG 2010
- TENX 1967
- Country
- PSHG Greece
- TENX United States
- Employees
- PSHG N/A
- TENX 6
- Industry
- PSHG Marine Transportation
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- TENX Health Care
- Exchange
- PSHG Nasdaq
- TENX Nasdaq
- Market Cap
- PSHG 20.1M
- TENX 21.6M
- IPO Year
- PSHG N/A
- TENX N/A
- Fundamental
- Price
- PSHG $1.37
- TENX $5.53
- Analyst Decision
- PSHG Strong Buy
- TENX Strong Buy
- Analyst Count
- PSHG 1
- TENX 3
- Target Price
- PSHG $6.50
- TENX $16.00
- AVG Volume (30 Days)
- PSHG 45.6K
- TENX 18.4K
- Earning Date
- PSHG 05-29-2025
- TENX 05-13-2025
- Dividend Yield
- PSHG N/A
- TENX N/A
- EPS Growth
- PSHG N/A
- TENX N/A
- EPS
- PSHG 1.12
- TENX N/A
- Revenue
- PSHG $87,445,000.00
- TENX N/A
- Revenue This Year
- PSHG N/A
- TENX N/A
- Revenue Next Year
- PSHG $31.45
- TENX N/A
- P/E Ratio
- PSHG $1.22
- TENX N/A
- Revenue Growth
- PSHG N/A
- TENX N/A
- 52 Week Low
- PSHG $1.31
- TENX $2.77
- 52 Week High
- PSHG $2.58
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- PSHG 37.20
- TENX 42.57
- Support Level
- PSHG $1.34
- TENX $4.63
- Resistance Level
- PSHG $1.55
- TENX $5.75
- Average True Range (ATR)
- PSHG 0.08
- TENX 0.42
- MACD
- PSHG -0.00
- TENX -0.04
- Stochastic Oscillator
- PSHG 20.83
- TENX 47.70
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.